Chiome IPO in Japan

Japanese antibody play Chiome Bioscience Inc. expects an IPO on the Mothers Market of the Tokyo Stock Exchange will give it enough capital to upgrade its ADLib mAb technology to work with human antibodies.

Chiome's Autonomously Diversifying Library technology currently generates antibodies through gene conversion in a chicken B cell line...